BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
8.91
-0.19 (-2.09%)
At close: May 29, 2026, 4:00 PM EDT
8.95
+0.04 (0.45%)
After-hours: May 29, 2026, 7:52 PM EDT
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, BioCryst Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $21.3. The average 1-year stock price forecast is 139.06% higher than the current stock price, while the lowest is $13 (+45.90%) and the highest is $32 (+259.15%).
Price Target: $21.3 (+139.06%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BioCryst Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $22 → $21 | Buy | Maintains | $22 → $21 | +135.69% | May 7, 2026 |
| Citizens JMP | Citizens JMP | Buy Maintains $25 → $28 | Buy | Maintains | $25 → $28 | +214.25% | May 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $32 | Buy | Maintains | $32 | +259.15% | May 7, 2026 |
| Needham | Needham | Buy Maintains $18 → $16 | Buy | Maintains | $18 → $16 | +79.57% | May 7, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $30 | Buy | Maintains | $30 | +236.70% | May 6, 2026 |
Financial Forecast
Revenue This Year
680.79M
from 874.84M
Decreased by -22.18%
Revenue Next Year
740.48M
from 680.79M
Increased by 8.77%
EPS This Year
-0.92
from 1.21
EPS Next Year
0.39
from -0.92
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 769.1M | 814.6M | ||||||
| Avg | 680.8M | 740.5M | ||||||
| Low | 618.9M | 662.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -12.1% | 19.7% | ||||||
| Avg | -22.2% | 8.8% | ||||||
| Low | -29.3% | -2.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.67 | 0.83 | ||||||
| Avg | -0.92 | 0.39 | ||||||
| Low | -2.72 | 0.01 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -44.5% | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.